Ocular Therapeutix (OCUL) News Today $7.96 +0.30 (+3.85%) As of 12:19 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 Time Period Ocular Therapeutix added to Analyst Current Favorites list at Raymond JamesMarch 27 at 12:25 AM | markets.businessinsider.comOcular Therapeutix, Inc. (NASDAQ:OCUL) Holdings Raised by Rosalind Advisors Inc.Rosalind Advisors Inc. lifted its stake in Ocular Therapeutix, Inc. (NASDAQ:OCUL - Free Report) by 27.5% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 1,128,700 shares of the biopharmaceutical company's stock after purchasing aMarch 23, 2025 | marketbeat.comVictory Capital Management Inc. Boosts Stock Position in Ocular Therapeutix, Inc. (NASDAQ:OCUL)Victory Capital Management Inc. boosted its stake in shares of Ocular Therapeutix, Inc. (NASDAQ:OCUL - Free Report) by 300.4% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 68,871 shares of the biopharmaceMarch 22, 2025 | marketbeat.comOcular Therapeutix (NASDAQ:OCUL) Shares Gap Up - What's Next?Ocular Therapeutix (NASDAQ:OCUL) Shares Gap Up - What's Next?March 19, 2025 | marketbeat.comRoyal Bank of Canada Begins Coverage on Ocular Therapeutix (NASDAQ:OCUL)Royal Bank of Canada began coverage on Ocular Therapeutix in a research report on Tuesday. They set an "outperform" rating and a $17.00 price objective for the company.March 19, 2025 | marketbeat.comOcular Therapeutix (NASDAQ:OCUL) Coverage Initiated at Royal Bank of CanadaMarch 19, 2025 | americanbankingnews.com3OCUL : What 4 Analyst Ratings Have To Say About Ocular TherapeutixMarch 18, 2025 | benzinga.comRBC Capital Initiates Coverage of Ocular Therapeutix (OCUL) with Outperform RecommendationMarch 18, 2025 | msn.comOcular Therapeutix (OCUL) Gets a Buy from RBC CapitalMarch 18, 2025 | markets.businessinsider.comOcular Therapeutix initiated with an Outperform at RBC CapitalMarch 18, 2025 | markets.businessinsider.comWhy Ocular Therapeutix Was Bumping Higher This WeekMarch 14, 2025 | fool.comOcular Therapeutix (NASDAQ:OCUL) Shares Up 9.7% - Should You Buy?Ocular Therapeutix (NASDAQ:OCUL) Stock Price Up 9.7% - Here's WhyMarch 12, 2025 | marketbeat.comOcular Therapeutix (NASDAQ:OCUL) Earns Buy Rating from Analysts at Needham & Company LLCNeedham & Company LLC assumed coverage on shares of Ocular Therapeutix in a research note on Tuesday. They set a "buy" rating and a $15.00 target price for the company.March 12, 2025 | marketbeat.comOcular Therapeutix initiated with a Buy at NeedhamMarch 11, 2025 | markets.businessinsider.comOcular rises as Needham issues new Buy on lead candidateMarch 11, 2025 | msn.comNeedham Initiates Coverage of Ocular Therapeutix (OCUL) with Buy RecommendationMarch 11, 2025 | msn.comEssex Investment Management Co. LLC Cuts Holdings in Ocular Therapeutix, Inc. (NASDAQ:OCUL)Essex Investment Management Co. LLC trimmed its holdings in shares of Ocular Therapeutix, Inc. (NASDAQ:OCUL - Free Report) by 12.7% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 387,248 sharesMarch 10, 2025 | marketbeat.comHC Wainwright Cuts Earnings Estimates for Ocular TherapeutixOcular Therapeutix, Inc. (NASDAQ:OCUL - Free Report) - Research analysts at HC Wainwright lowered their Q1 2025 EPS estimates for Ocular Therapeutix in a report released on Tuesday, March 4th. HC Wainwright analyst Y. Chen now expects that the biopharmaceutical company will post earnings of ($0.3March 7, 2025 | marketbeat.comOcular Therapeutix, Inc. (NASDAQ:OCUL) Receives Average Rating of "Moderate Buy" from AnalystsShares of Ocular Therapeutix, Inc. (NASDAQ:OCUL - Get Free Report) have earned an average rating of "Moderate Buy" from the six ratings firms that are currently covering the firm, Marketbeat reports. One research analyst has rated the stock with a hold recommendation and five have issued a buy reMarch 7, 2025 | marketbeat.comOcular Therapeutix: Axpaxli's Dual Trial Strategy And Blockbuster PotentialMarch 6, 2025 | seekingalpha.comOcular Therapeutix (NASDAQ:OCUL) Trading Up 3.3% - Should You Buy?Ocular Therapeutix (NASDAQ:OCUL) Trading Up 3.3% - Here's WhyMarch 5, 2025 | marketbeat.comTruist Financial Corp Acquires Shares of 50,000 Ocular Therapeutix, Inc. (NASDAQ:OCUL)Truist Financial Corp acquired a new stake in shares of Ocular Therapeutix, Inc. (NASDAQ:OCUL - Free Report) in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor acquired 50,000 shares of the biopharmaceutical company's stock, valMarch 5, 2025 | marketbeat.comOcular Therapeutix shares tumble on earnings missMarch 5, 2025 | in.investing.comScotiabank Sticks to Their Buy Rating for Ocular Therapeutix (OCUL)March 5, 2025 | markets.businessinsider.comOcular Therapeutix, Inc. (NASDAQ:OCUL) Q4 2024 Earnings Call TranscriptMarch 5, 2025 | msn.comOcular Therapeutix Stock Sees Worst Day In Nearly A Year On Q4 Miss, But Retail Sees A ComebackMarch 4, 2025 | msn.comHC Wainwright Reaffirms Buy Rating for Ocular Therapeutix (NASDAQ:OCUL)HC Wainwright reissued a "buy" rating and issued a $15.00 price objective on shares of Ocular Therapeutix in a research note on Tuesday.March 4, 2025 | marketbeat.comOcular Therapeutix reports Q4 EPS (29c), consensus (22c)March 3, 2025 | markets.businessinsider.comOcular Therapeutix outlines AXPAXLI NDA submission timeline with SOL-1 topline data expected Q1 2026March 3, 2025 | msn.comOcular Therapeutix Shares Drop After Wider-Than-Expected 4Q LossMarch 3, 2025 | marketwatch.comOcular Therapeutix Sees Unusually High Options Volume (NASDAQ:OCUL)Ocular Therapeutix, Inc. (NASDAQ:OCUL - Get Free Report) was the recipient of some unusual options trading on Monday. Stock investors bought 7,643 call options on the stock. This is an increase of 1,707% compared to the average daily volume of 423 call options.March 3, 2025 | marketbeat.comOcular Therapeutix (NASDAQ:OCUL) Shares Gap Down on Disappointing EarningsOcular Therapeutix (NASDAQ:OCUL) Shares Gap Down After Earnings MissMarch 3, 2025 | marketbeat.comOcular Therapeutix (NASDAQ:OCUL) Releases Quarterly Earnings ResultsOcular Therapeutix (NASDAQ:OCUL - Get Free Report) posted its quarterly earnings data on Monday. The biopharmaceutical company reported ($0.29) earnings per share for the quarter, missing the consensus estimate of ($0.24) by ($0.05). Ocular Therapeutix had a negative return on equity of 45.18% and a negative net margin of 283.74%.March 3, 2025 | marketbeat.comPravin Dugel Sells 21,475 Shares of Ocular Therapeutix, Inc. (NASDAQ:OCUL) StockOcular Therapeutix, Inc. (NASDAQ:OCUL - Get Free Report) insider Pravin Dugel sold 21,475 shares of the firm's stock in a transaction on Monday, February 24th. The shares were sold at an average price of $6.87, for a total transaction of $147,533.25. Following the completion of the sale, the insider now owns 3,520,318 shares in the company, valued at $24,184,584.66. The trade was a 0.61 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this hyperlink.February 27, 2025 | marketbeat.comOcular Therapeutix (OCUL) Projected to Post Earnings on MondayOcular Therapeutix (NASDAQ:OCUL) will be releasing earnings before the market opens on Monday, March 3, Financial Modeling Prep reports. (Register for Conference Call at http://mmm.wallstreethorizon.com/u.asp?u=669322)February 25, 2025 | marketbeat.comOcular Therapeutix™ to Present at Two Investor Conferences in MarchFebruary 25, 2025 | markets.businessinsider.comOcular Therapeutix™ to Report Fourth Quarter and Full Year 2024 Results on March 3, 2025February 24, 2025 | globenewswire.comHussman Strategic Advisors Inc. Takes Position in Ocular Therapeutix, Inc. (NASDAQ:OCUL)Hussman Strategic Advisors Inc. bought a new stake in shares of Ocular Therapeutix, Inc. (NASDAQ:OCUL - Free Report) in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 105,000 shares of the biopharmaceutical company's sFebruary 22, 2025 | marketbeat.comOcular Therapeutix CEO gets new compensation packageFebruary 14, 2025 | msn.comLegato Capital Management LLC Trims Stock Holdings in Ocular Therapeutix, Inc. (NASDAQ:OCUL)Legato Capital Management LLC trimmed its stake in Ocular Therapeutix, Inc. (NASDAQ:OCUL - Free Report) by 23.2% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 114,820 shares of the biopharmaceutical comFebruary 14, 2025 | marketbeat.comOcular Therapeutix, Inc. (NASDAQ:OCUL) Given Consensus Recommendation of "Moderate Buy" by AnalystsOcular Therapeutix, Inc. (NASDAQ:OCUL - Get Free Report) has received an average recommendation of "Moderate Buy" from the six ratings firms that are covering the firm, MarketBeat.com reports. One research analyst has rated the stock with a hold recommendation and five have assigned a buy recommeFebruary 10, 2025 | marketbeat.comRaymond James maintains $19 target on Ocular Therapeutix stockFebruary 6, 2025 | msn.comOcular Therapeutix, Inc. (NASDAQ:OCUL) Insider Sells $49,399.84 in StockFebruary 5, 2025 | insidertrades.comOcular Therapeutix CFO Donald Notman sells $136,238 in stockFebruary 5, 2025 | msn.comDonald Notman Sells 6,301 Shares of Ocular Therapeutix, Inc. (NASDAQ:OCUL) StockOcular Therapeutix, Inc. (NASDAQ:OCUL - Get Free Report) insider Donald Notman sold 6,301 shares of the company's stock in a transaction dated Friday, January 31st. The stock was sold at an average price of $7.84, for a total transaction of $49,399.84. Following the sale, the insider now directly owns 204,563 shares in the company, valued at $1,603,773.92. This represents a 2.99 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link.February 4, 2025 | marketbeat.comOcular Therapeutix, Inc. (NASDAQ:OCUL) Insider Sells $86,839.39 in StockOcular Therapeutix, Inc. (NASDAQ:OCUL - Get Free Report) insider Donald Notman sold 11,119 shares of Ocular Therapeutix stock in a transaction dated Tuesday, February 4th. The shares were sold at an average price of $7.81, for a total transaction of $86,839.39. Following the transaction, the insider now directly owns 193,444 shares of the company's stock, valued at approximately $1,510,797.64. This trade represents a 5.44 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.February 4, 2025 | marketbeat.comOcular Therapeutix™ Announces Upcoming Presentations at the Angiogenesis, Exudation, and Degeneration 2025 Virtual MeetingFebruary 3, 2025 | globenewswire.comOcular Therapeutix IncJanuary 29, 2025 | money.usnews.comOcular Therapeutix (NASDAQ:OCUL) Share Price Passes Below 200-Day Moving Average - Should You Sell?Ocular Therapeutix (NASDAQ:OCUL) Shares Pass Below 200 Day Moving Average - What's Next?January 28, 2025 | marketbeat.comRoundAngle Advisors LLC Takes $1.70 Million Position in Ocular Therapeutix, Inc. (NASDAQ:OCUL)RoundAngle Advisors LLC acquired a new position in shares of Ocular Therapeutix, Inc. (NASDAQ:OCUL - Free Report) in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor acquired 198,456 shares of the biopharmaceutical comJanuary 20, 2025 | marketbeat.com Remove Ads Get Ocular Therapeutix News Delivered to You Automatically Sign up to receive the latest news and ratings for OCUL and its competitors with MarketBeat's FREE daily newsletter. Email Address OCUL Media Mentions By Week OCUL Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. OCUL News Sentiment▼1.070.82▲Average Medical News Sentiment OCUL News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. OCUL Articles This Week▼45▲OCUL Articles Average Week Remove Ads Get Ocular Therapeutix News Delivered to You Automatically Sign up to receive the latest news and ratings for OCUL and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies ADMA News Today PTCT News Today RNA News Today ACLX News Today OGN News Today ZLAB News Today RARE News Today SWTX News Today AKRO News Today ALVO News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:OCUL) was last updated on 3/27/2025 by MarketBeat.com Staff From Our PartnersA market crash is coming—here’s whenThe stock market cycle I've used to identify the most likely day of the next market crash is the exact same in...Chaikin Analytics | SponsoredYour Wealth is Under AttackPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredA brutally honest economic warning for 2025 (see proof)New York Times best-selling financial author and world-renowned economist Addison Wiggin (a man who’s worked s...Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredEx CIA predicts 40% “double crash” – April 11The scientists here don’t study deadly viruses… directed energy weapons… or even weather control technology… ...Paradigm Press | Sponsored“Amazon Coin” set to outperform BitcoinChris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ocular Therapeutix, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Ocular Therapeutix With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy OCUL Stock Free OCUL Stock Alerts